
NOVAVIDO IS BORN, THE START-UP THAT WILL STUDY THE FIRST ARTIFICIAL LIQUID RETINA ON HUMANS
Alfasigma, Utopia SIS, David Chiossone Institute and Club2021 will invest 6 million euros with two rounds of seeding to initiate the final clinical phase of experimentation of this possible solution for neurodegenerative diseases of the retina.
The project will focus on the development of an injectable and biocompatible device, called 'liquid retina', which would allow the partial recovery of sight of people suffering from partial blindness due to retinal degenerative diseases.